Drugmaker Daiichi Sankyo Co. and U.S. partner Eli Lilly & Co. sought to reassure investors Friday that a highly anticipated blood thinner remains on track for approval, despite escalating concerns of further delays by federal health regulators.
Wall Street has big hopes for the potential blockbuster medication, called prasugrel, but its enthusiasm was dampened in late September, when the the Food and Drug Administration postponed its decision for a second time. Recent media reports speculate that additional FDA meetings may push back the ruling until March.
In a joint statement, the companies said they had not been contacted regarding any regulatory action or advisory committee review of the drug.